<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928846</url>
  </required_header>
  <id_info>
    <org_study_id>M18-868</org_study_id>
    <secondary_id>2021-001811-94</secondary_id>
    <nct_id>NCT04928846</nct_id>
  </id_info>
  <brief_title>A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer is a condition where cells in a specific part of body grow and reproduce&#xD;
      uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which&#xD;
      cancer cells form in the tissues of the lung. The purpose of this study is to determine if&#xD;
      telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab&#xD;
      vedotin is in adult participants with NSCLC who have previously been treated. Change in&#xD;
      disease activity and adverse events will be assessed.&#xD;
&#xD;
      Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC.&#xD;
      Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group&#xD;
      receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel.&#xD;
      Approximately 698 adult participants with c-Met overexpressing NSCLC will be enrolled in the&#xD;
      study in approximately 250 sites worldwide.&#xD;
&#xD;
      Participants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks&#xD;
      until meeting study drug discontinuation criteria.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests,&#xD;
      checking for side effects and completing questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2021</start_date>
  <completion_date type="Anticipated">March 9, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) per Independent Central Review (ICR)</measure>
    <time_frame>Up to approximately 39 months</time_frame>
    <description>PFS is defined as the time from randomization to the first occurrence of radiographic progression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) per ICR or death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 39 months</time_frame>
    <description>OS is defined as the time from randomization to the event of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 58.25 months</time_frame>
    <description>ORR is defined as the percentage of participants with a complete response (CR) or partial response (PR) based on RECIST v1.1, per ICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to approximately 58.25 months</time_frame>
    <description>DoR is defined for responders as the time from response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause per ICR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS per Investigator Assessment</measure>
    <time_frame>Up to approximately 58.25 months</time_frame>
    <description>PFS is defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 per investigator or death from any cause. Participants with no PFS event will be censored at the last evaluable radiographic assessment per investigator. Participants with no event and no evaluable post-baseline assessment will be censored at randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration in Cough, Pain or Dyspnea as measured by the Cough, Pain and Dyspnea items of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (EORTC QLQ-LC13)</measure>
    <time_frame>Up to approximately 58.25 months</time_frame>
    <description>The EORTC QLQ-LC13 is the lung cancer specific module of the core EORTC QLQ-C30. The QLQ-LC13 includes 13 questions that include both multi-item and single-item scales of lung cancer-associated symptoms (e.g., pain, coughing, hemoptysis, and dyspnea) and side-effects from chemo- and radiotherapy (e.g., hair loss, neuropathy, sore mouth and dysphagia). All scale and item scores are linearly transformed to a 0 to 100 scale, with higher scores representing increasing symptom levels or impacts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Deterioration of Physical Functioning as measured by the Physical Functioning domain of the EORTC-QLQ-Core 30 (EORTC QLQ-C30).</measure>
    <time_frame>Up to approximately 58.25 months</time_frame>
    <description>The EORTC QLQ-C30 assesses health-related quality of life in cancer patients participating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales (physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue, pain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as well as subscales assessing global health/quality of life and financial impact. Raw scores are transformed to a scale of 0 to 100, with higher scores representing better functioning/quality of life and greater symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Quality of Life as measured by the Global Health Status/Quality of Life Domain of the EORTC QLQ-C30.</measure>
    <time_frame>Up to approximately 58.25 months</time_frame>
    <description>The EORTC QLQ-C30 assesses health-related quality of life in cancer patients participating in clinical trials. The EORTC QLQ-C30 comprises 5 functional scales (physical, role, emotional, social, cognitive), 8 single-item symptom scales (fatigue, pain, nausea/vomiting, appetite loss, constipation, diarrhea, insomnia, and dyspnea), as well as subscales assessing global health/quality of life and financial impact. Raw scores are transformed to a scale of 0 to 100, with higher scores representing better functioning/quality of life and greater symptom burden.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">698</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Telisotuzumab Vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive docetaxel every 3 weeks until meeting study drug discontinuation criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Telisotuzumab Vedotin</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Telisotuzumab Vedotin</arm_group_label>
    <other_name>ABBV-399</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>IV Infusion</description>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as&#xD;
             assessed by an AbbVie designated immunohistochemistry (IHC) laboratory.&#xD;
&#xD;
          -  Archival or fresh tumor material must be submitted for assessment of c-Met levels&#xD;
             during the Pre-Screening period. Tumor material from the primary tumor site and/or&#xD;
             metastatic sites are allowed.&#xD;
&#xD;
          -  A histologically documented non-squamous cell NSCLC that is locally advanced or&#xD;
             metastatic.&#xD;
&#xD;
          -  A known epidermal growth factor receptor (EGFR) activating mutation status.&#xD;
&#xD;
          -  Actionable alterations in genes other than EGFR .&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version&#xD;
             1.1.&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.&#xD;
&#xD;
          -  Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the&#xD;
             locally advanced or metastatic setting.&#xD;
&#xD;
               -  Neoadjuvant and adjuvant systemic cytotoxic chemotherapy will count as a prior&#xD;
                  line for eligibility purposes if progression occurred within 6 months of the end&#xD;
                  of therapy.&#xD;
&#xD;
          -  Have progressed on at least 1 line of prior therapy for locally advanced/metastatic&#xD;
             NSCLC:&#xD;
&#xD;
               -  Participants WITHOUT an actionable gene alteration: must have progressed on (or&#xD;
                  be considered ineligible for) platinum-based chemotherapy and immune checkpoint&#xD;
                  inhibitor (as monotherapy or in combination with chemotherapy).&#xD;
&#xD;
               -  Participants WITH an actionable gene alteration for which immune checkpoint&#xD;
                  inhibitor therapy is not standard of care (e.g., anaplastic lymphoma kinase [ALK]&#xD;
                  translocation): must have progressed on (or be considered ineligible for)&#xD;
                  anti-cancer therapy targeting driver gene alterations and platinum-based&#xD;
                  chemotherapy.&#xD;
&#xD;
                    -  Participants with actionable gene alterations for which immune checkpoint&#xD;
                       inhibitor is standard of care must have also progressed on (or be considered&#xD;
                       ineligible for) immune checkpoint inhibitor (as monotherapy or in&#xD;
                       combination with chemotherapy).&#xD;
&#xD;
          -  Must be considered appropriate for docetaxel therapy based on the assessment of the&#xD;
             treating physician.&#xD;
&#xD;
          -  Participants with metastases to the central nervous system (CNS) are eligible only&#xD;
             after definitive therapy (such as surgery or radiotherapy) is provided and:&#xD;
&#xD;
               -  There is no evidence of progression of CNS metastases at least 4 weeks after&#xD;
                  definitive therapy.&#xD;
&#xD;
               -  They are asymptomatic and off or on a stable or reducing dose of systemic&#xD;
                  steroids and/or anticonvulsants for at least 2 weeks prior to first dose of&#xD;
                  telisotuzumab vedotin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with adenosquamous histology.&#xD;
&#xD;
          -  Actionable epidermal growth factor receptor (EGFR) activating mutations.&#xD;
&#xD;
          -  Participants who have received prior c-Met-targeted antibodies.&#xD;
&#xD;
          -  Participants who have received prior docetaxel therapy.&#xD;
&#xD;
          -  A history of other malignancies except:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease present&#xD;
                  for &gt;=2 years before the first dose of study drug and felt to be at low risk for&#xD;
                  recurrence by investigator.&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease.&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without current evidence of disease.&#xD;
&#xD;
          -  A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography (CT) scan. A history of&#xD;
             prior radiation pneumonitis in the radiation field (fibrosis) is permitted.&#xD;
&#xD;
          -  Unresolved clinically significant adverse event (AE) &gt;= Grade 2 from prior anticancer&#xD;
             therapy, except for alopecia or anemia.&#xD;
&#xD;
          -  Major surgery within 21 days prior to the first dose of telisotuzumab vedotin.&#xD;
&#xD;
          -  Clinically significant condition(s) as listed in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence Alaska Medical Center /ID# 233324</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508-4684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eisenhower Health Lucy Curci Cancer Center /ID# 233189</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270-3221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Moanalua Medical Center /ID# 238363</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819-1469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward-Elmhurst Cancer Center - Naperville /ID# 238552</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540-6508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascension Providence Hospital /ID# 231970</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075-4825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital /ID# 232190</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197-1051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hulston Cancer Center /ID# 232226</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807-5287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center /ID# 238364</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Northwest /ID# 234123</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute /ID# 239635</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center - Lubbock /ID# 238491</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Austral /ID# 239860</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <state>Ciuadad Autonoma De Buenos Aires</state>
        <zip>1019</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas Clinica Viedma S.A. /ID# 232339</name>
      <address>
        <city>Viedma</city>
        <state>Rio Negro</state>
        <zip>8500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Penzing /ID# 230700</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Floridsdorf /ID# 230608</name>
      <address>
        <city>Vienna</city>
        <state>Wien</state>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 232467</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen /ID# 239971</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Klina /ID# 239853</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Catolica del Maule /ID# 231294</name>
      <address>
        <city>Talca</city>
        <state>Maule</state>
        <zip>3461341</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icegclinic /Id# 231212</name>
      <address>
        <city>La Florida</city>
        <state>Region Metropolitana Santiago</state>
        <zip>8241479</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedad Prosalud Montes y Orlandi /ID# 231154</name>
      <address>
        <city>Providencia</city>
        <state>Region Metropolitana Santiago</state>
        <zip>7500713</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Arturo Lopez Perez /ID# 231151</name>
      <address>
        <city>Providencia</city>
        <state>Region Metropolitana Santiago</state>
        <zip>7500921</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedad Oncovida /ID# 231152</name>
      <address>
        <city>Providencia</city>
        <state>Region Metropolitana Santiago</state>
        <zip>7510032</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Chest Hospital /ID# 231899</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital /ID# 231923</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University /ID# 238591</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Cancer Center /ID# 231855</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 231904</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital /ID# 231943</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital /ID# 231791</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantong Tumor Hospital /ID# 232424</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University /ID# 231934</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University /ID# 231935</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University /ID# 232023</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 232032</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital, Zhejiang Province /ID# 232021</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University /ID# 232005</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University /ID# 233703</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital /ID# 231897</name>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital /ID# 231839</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital /ID# 233176</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital Of Guangdong Medical University /ID# 233317</name>
      <address>
        <city>Zhanjiang</city>
        <zip>524011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav /ID# 232426</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Novy Jicin, a. s., clen skupiny Agel /ID# 232427</name>
      <address>
        <city>Novy Jicin</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie /ID# 240141</name>
      <address>
        <city>Paris CEDEX 05</city>
        <state>Ile-de-France</state>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Mannheim /ID# 238331</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 239658</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel /ID# 240142</name>
      <address>
        <city>Kassel</city>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chest Diseases of Athens SOTIRIA /ID# 230824</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital /ID# 239170</name>
      <address>
        <city>Piraeus</city>
        <state>Attiki</state>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont /ID# 233801</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdu-Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Edith Wolfson Medical Center /ID# 233781</name>
      <address>
        <city>Holon</city>
        <zip>5822000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center /ID# 238606</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Perugia /ID# 238473</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C.S Istituto Tumori Giovanni Paolo II /ID# 238696</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale di Cremona /ID# 238698</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Giovanni Addolorata /ID# 238618</name>
      <address>
        <city>Rome</city>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Sette Laghi /ID# 238536</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 233775</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center /ID# 238533</name>
      <address>
        <city>Fukuoka shi</city>
        <state>Fukuoka</state>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center /ID# 233723</name>
      <address>
        <city>Ota-shi</city>
        <state>Gunma</state>
        <zip>373-0828</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital /ID# 239027</name>
      <address>
        <city>Shiwa-gun</city>
        <state>Iwate</state>
        <zip>028-3695</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center /ID# 234198</name>
      <address>
        <city>Natori-shi</city>
        <state>Miyagi</state>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital /ID# 239344</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Habikino Medical Center /ID# 239989</name>
      <address>
        <city>Habikino-shi</city>
        <state>Osaka</state>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital /ID# 233476</name>
      <address>
        <city>Hirakata-shi</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital /ID# 238895</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University Hospital /ID# 234004</name>
      <address>
        <city>Wakayama-shi</city>
        <state>Wakayama</state>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA University Bundang Medical Center /ID# 233318</name>
      <address>
        <city>Seongnam si</city>
        <state>Gyeonggido</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital /ID# 233319</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggido</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital /ID# 234244</name>
      <address>
        <city>Jinju</city>
        <state>Gyeongsangnamdo</state>
        <zip>52727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital /ID# 233711</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Fray Antonio Alcalde /ID# 238488</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clínica Chapultepec SA de CV /ID# 231928</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58260</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez /ID# 231880</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicios de Oncologia Medica Integral /ID# 232098</name>
      <address>
        <city>Mexico</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research &amp; Oncology Oaxaca /ID# 231883</name>
      <address>
        <city>Oaxaca</city>
        <zip>68020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum /ID# 233932</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki /ID# 239024</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 239363</name>
      <address>
        <city>Rzeszow</city>
        <state>Podkarpackie</state>
        <zip>35-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncocenter - Oncologie Clinica Srl /Id# 239103</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300166</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL /ID# 240826</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sc Oncolab Srl /Id# 239105</name>
      <address>
        <city>Craiova</city>
        <zip>200385</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC RTC Radiology Therapeutic Center SRL /ID# 240744</name>
      <address>
        <city>Otopeni</city>
        <zip>075100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Sigmedical Services SRL /ID# 239108</name>
      <address>
        <city>Suceava</city>
        <zip>720214</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vychodoslovensky onkologicky ustav, a.s. /ID# 230085</name>
      <address>
        <city>Kosice</city>
        <state>Kosicky Kraj</state>
        <zip>041 91</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 230084</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava Nemocnica Ruzinov /ID# 232216</name>
      <address>
        <city>Bratislava</city>
        <zip>821 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Nove Zamky /ID# 230086</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 34</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research Site /ID# 230841</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Medical Group PTY Ltd /ID# 230843</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology Steve Biko Academic Hospital /ID# 230883</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orebro Universitetssjukhuset /ID# 230864</name>
      <address>
        <city>Orebro</city>
        <state>Orebro Lan</state>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital Lund /ID# 229944</name>
      <address>
        <city>Lund</city>
        <state>Skane Lan</state>
        <zip>SE 221 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital /ID# 229943</name>
      <address>
        <city>Gothenburg</city>
        <state>Vastra Gotalands Lan</state>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital /ID# 229853</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital /ID# 238394</name>
      <address>
        <city>Changhua County</city>
        <zip>50006</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital - Hsinchu branch /ID# 238393</name>
      <address>
        <city>Hsinchu City</city>
        <zip>30059</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hualien Tzu Chi Hospital /ID# 238398</name>
      <address>
        <city>Hualien City</city>
        <zip>97002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E-DA Cancer Hospital /ID# 239718</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital /ID# 238444</name>
      <address>
        <city>Taichung</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital /ID# 238378</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MacKay Memorial Hospital /ID# 238392</name>
      <address>
        <city>Taipei City</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital /ID# 238380</name>
      <address>
        <city>Taipei City</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Park Izmir Hastanesi /ID# 234209</name>
      <address>
        <city>Karsiyaka</city>
        <state>Izmir</state>
        <zip>35575</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adana Acıbadem Hospital /ID# 234208</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara City Hospital /ID# 234210</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inonu Universitesi Turgut Ozal /ID# 234038</name>
      <address>
        <city>Battalgazi/malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag University Medical Faculty /ID# 234205</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dicle Universitesi Tip /ID# 234036</name>
      <address>
        <city>Diyarbakir</city>
        <zip>21200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya University Medical Facu /ID# 234035</name>
      <address>
        <city>Edirne, Istanbul</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bagcilar Medipol Mega Universite Hastanesi /ID# 234211</name>
      <address>
        <city>Istanbul</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty /ID# 234039</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baskent Universitesi Adana Dr. Turgut Noyan Uyg. Ve Arast. Merkezi /ID# 238337</name>
      <address>
        <city>Yuregir</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Nonprofit Enterprise Regional Oncology Center of Kirovograd Regional Coun /ID# 233220</name>
      <address>
        <city>Kropyvnytskyi</city>
        <state>Kirovohradska Oblast</state>
        <zip>25011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI Zaporizhzhia Regional Clinical Oncological Dispensary /ID# 232519</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Zaporizka Oblast</state>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal non-profit enterprise Regional Center of Oncology /ID# 232518</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Medical Center &quot;VERUM EXPERT &quot; /ID# 233213</name>
      <address>
        <city>Kyiv</city>
        <zip>03039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNE Podillia Regional Oncology Center of Vinnytsia Regional Council /ID# 232520</name>
      <address>
        <city>Ukraine</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of &quot;VISION PARTNER&quot; LLC /ID# 233221</name>
      <address>
        <city>Київ</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Mriya Med-Service&quot; /ID# 232521</name>
      <address>
        <city>Кривий Ріг</city>
        <zip>50000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-Met Overexpressing Non-Small Cell Lung Cancer</keyword>
  <keyword>c-Met NSCLC</keyword>
  <keyword>Telisotuzumab Vedotin</keyword>
  <keyword>ABBV-399</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Cancer</keyword>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/ith-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

